Figure 26. Effects of FDA-approved pharmacological ADHD treatment on ADHD symptoms (SMD) The figure is a forest plot that displays all studies that reported on the effects of FDA-approved pharmacological ADHD treatment on ADHD symptoms using the standardized mean difference (SMD). The figure also shows the pooled result across studies.

Figure 26Effects of FDA-approved pharmacologic ADHD treatment on ADHD symptoms (SMD)

Notes: ADHD = attention deficit hyperactivity disorder, FDA = Food and Drug Administration, NS-ALA-CLON = clonidine, NS-ALA-GXR = guanfacine, NS-NRI-ATX = atomoxetine, NS-NRI-VLX = viloxazine, S-AMPH-LDX = lisdexamfetamine dimesylate, S-AMPH-MAS = mixed amphetamine salts, S-MPH-IR = immediate release methylphenidate, S-MPH-OROS = osmotic-release oral system methylphenidate, S-MPH-TP = methylphenidate transdermal patch, RE = random effects, SMD = Standardized Mean Difference

From: 5, Results: Treatment of ADHD

Cover of ADHD Diagnosis and Treatment in Children and Adolescents
ADHD Diagnosis and Treatment in Children and Adolescents [Internet].
Comparative Effectiveness Review, No. 267.
Peterson BS, Trampush J, Maglione M, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.